Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma

 Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma

Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular Carcinoma

Shots:

  • The P-III IMbrave150 study involve assessing of Tecentriq (1200 mg on day 1 of each 21-day cycle) in combination with Avastin (15 mg/kg on day 1 of each 21-day cycle) vs SoC sorafenib in 501 patients in a ratio (2:1) with unresectable HCC with no prior treatment with systemic therapy
  • The P-III III IMbrave150 study resulted in meeting its co-1EPs demonstrating improvement in OS and PFS, no new safety signals were observed
  • The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq’s ability to restore anti-cancer immunity, by inhibiting VEGF related immunosuppression. The results from the study will be submitted to health authorities globally, including the US FDA, EMA & NMPA

Click here to­ read full press release/ article | Ref: Roche | Image: Sfgate

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post